RDC (Radionuclide Drug Conjugate), a novel trend in bioconjugation drug development, has multiple uses in clinical diagnostic and treatment. Four components are needed in RDC, including radionuclide, chelator, linker, and delivery part. Three kinds of delivery parts, including antibodies, small molecules, and peptides are utilized in RDC. Focusing on RDC development for decades with our professional RDC development platform, Rdcthera is capable to provide premium quality and cost-effective services throughout the whole process of RDC development. Fig.1 Illustration of RDC targeting the cancer cell.Fig.1 Illustration of RDC targeting the cancer cell. Overview of RDC RDC is a bifunctional radiopharmaceutical with two essential parts, including a radionuclide and a targeting molecule. The radionuclide is utilized as the effective part to conduct cancer cell damaging and diagnostic imaging at the cell level, while the targeting molecule is the delivery vehicle to drive the RDC to the diseased tissue. Based on the different types of targeting molecules, the RDC can be divided into three categories, containing antibody-based RDC, small molecule-based RDC, and peptide-based RDC.